预约演示
更新于：2025-04-24
Posaconazole
泊沙康唑
更新于：2025-04-24
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C37H42F2N8O4 |
InChIKeyRAGOYPUPXAKGKH-XAKZXMRKSA-N |
CAS号171228-49-2 |
关联
176
项与 泊沙康唑 相关的临床试验ChiCTR2500098742
A multicenter, randomized controlled phase II clinical study of oral posaconazole combined with chemotherapy and PD-1 inhibitors as neoadjuvant treatment for early or locally advanced triple-negative breast cancer
CTR20250761
泊沙康唑口服混悬液在健康受试者中进行的单中心、单剂量、2制剂、4周期、2序列、开放、随机、完全重复交叉的生物等效性试验。
DRKS00036219
Importance of therapeutic drug monitoring (TDM) of posaconazole in hematologic patients - Posa-TDM
100 项与 泊沙康唑 相关的临床结果
登录后查看更多信息
100 项与 泊沙康唑 相关的转化医学
登录后查看更多信息
100 项与 泊沙康唑 相关的专利（医药）
登录后查看更多信息
5,135
项与 泊沙康唑 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Emerging antifungal resistance in
Trichophyton mentagrophytes
: insights from susceptibility profiling and genetic mutation analysis
Article
作者: Richardson, Malcolm ; Bai, Lin ; Richardson, Riina ; Shao, Jin ; Shao, Yakun ; Wan, Zhe ; Yu, Jin ; Song, Yinggai ; Verweij, Paul ; Li, Ruoyu ; de Hoog, Sybren
ABSTRACTTrichophyton species, the leading cause of dermatophytosis globally, are increasingly resistant to antifungal treatments, concerns about effective management strategies. In light of the absence of established resistance criteria for terbinafine and azoles, coupled with a dearth of research on resistance mechanisms in Trichophyton, antifungal susceptibility and drug resistance gene diversity were analyzed across 64 T. mentagrophytes, 65 T. interdigitale, and 2 T. indotineae isolates collected in China between 1999 and 2024 and 101 published T. indotineae strains. Analyses of the minimum inhibitory concentrations (MICs) of terbinafine, itraconazole, voriconazole, posaconazole, and isavuconazole revealed a concerning increase in T. indotineae with terbinafine resistance, including two novel isolates from China. Compared with T. interdigitale, T. mentagrophytes presented higher terbinafine MICs but similar azole susceptibility. Notably, 27 T. interdigitale isolates were classified as non-wild-type for terbinafine. Genetic diversity was analyzed for the SQLE, CYP51A and CYP51B gene. Specifically, T. indotineae isolates presented SQLE protein changes linked to terbinafine resistance. SQLE diversity was linked to terbinafine sensitivity, whereas alterations in CYP51A were associated with itraconazole sensitivity, with notable statistical significance evident across various protein isoforms. The relationship between protein diversity and drug sensitivity is presented in detail. Together, these findings highlight a growing prevalence of antibiotic resistance among Trichophyton and identify potential target genes for new therapies, underscoring the need for ongoing monitoring and offering directions for novel therapeutics.
2025-07-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Posaconazole effectiveness in rare invasive fungal infections: A systematic literature review
Review
作者: Simon, Alyssa ; Campbell, Havilland ; Bernauer, Mark ; Kaminski, Allysen ; Cossrow, Nicole ; Patel, Dipen ; Waskin, Hetty
INTRODUCTION:
Mucormycosis, hyalohyphomycosis, chromoblastomycosis, and fungal mycetoma are rare invasive fungal infections (IFIs) that cause significant morbidity and mortality in immunocompromised patients. Few effective treatment options are available for these IFIs.
METHODS:
We performed a systematic literature review of MEDLINE and Embase to identify studies published from 2005 (year of posaconazole approval) to 22 October 2022, reporting the efficacy/effectiveness of posaconazole monotherapy or combination therapy for treating mucormycosis, hyalohyphomycosis, chromoblastomycosis, and mycetoma. Positive outcomes or positive clinical outcomes were defined as reporting of a positive efficacy/effectiveness measure (i.e. no relapse, response, cure, radiological improvement, clinical/symptom improvement, or survived therapy).
RESULTS:
Of 3207 articles identified (after removing duplicates), 533 articles (mostly case reports) were included. Positive clinical outcomes with posaconazole therapy were observed in most patients with mucormycosis (74.8%, 1197/1601), hyalohyphomycosis (58.5%, 62/106), chromoblastomycosis (90.5%, 19/21), and mycetoma (100%, 5/5). Overall survival was around 70% or greater across the IFIs examined. Positive response was higher in second-line monotherapy than first-line monotherapy in mucormycosis and chromoblastomycosis. Higher mortality was observed with combination therapy than monotherapy in mucormycosis and hyalohyphomycosis infections (except for first-line use in mucormycosis). Positive clinical outcome was 78.6% and overall survival was 78.6% in 323 coronavirus disease-associated mucormycosis infection cases.
CONCLUSIONS:
Despite the rarity of these IFIs, substantial data have been published since posaconazole was initially approved in 2005, and the real-world case reports demonstrate that posaconazole is an effective therapeutic option alone or in combination for the treatment of these rare IFIs.
2025-06-01Journal of Stomatology Oral and Maxillofacial Surgery
Delayed maxillary reconstruction following mucormycosis: A comprehensive analysis of surgical strategies and outcomes
Article
作者: Garg, Paheli ; Goil, Pradeep ; Charan Pahari, Dr Kaushal ; Charan Pahari, Kaushal ; Goil, Dr Pradeep ; Vashistha, Aakansha ; Vashistha, Dr Aakansha ; Garg, Dr Paheli
STUDY DESIGN:
This study is a prospective observational study conducted over two years from December 2020 to March 2023 at the Department of Plastic and Reconstructive Surgery.
OBJECTIVE:
To evaluate the outcomes of delayed reconstruction in patients with maxillectomy defects post-COVID-19 associated mucormycosis, focusing on safety, morbidity, and aesthetic results.
METHODS:
Fifty patients with post-COVID-19 mucormycosis and maxillectomy defects without skin involvement were included. These patients underwent radical debridement and were treated with Amphotericin B followed by Posaconazole therapy until clinical and radiological resolution of the disease. Reconstruction was performed after a minimum of six months post-maxillectomy. Flaps used for reconstruction included the radial forearm free flap (RAFF), anterolateral thigh flap (ALT), and free fibula osteomyocutaneous flap, planned using a 3D-printed model. Follow-up was conducted weekly for the first month and monthly for the next two months, with semiannual visits thereafter.
RESULTS:
Of the 50 patients, 42 % were male, and 58 % were female, with a mean age of 43 ± 8.75 years. Most patients (88 %) were diabetic. Maxillectomy defects were categorized as type IIA, IIB, IIIA, IIIB, and IV based on the Cordeiro classification. Four flaps (8 %) required re-exploration, with three salvaged. Complications included marginal flap necrosis (4 %) and oro-nasal fistula (2 %). The average hospital stay was six days, extended to ten days for re-explored cases. Flap dimensions varied with the largest being 62 cm² for the free fibula flap.
CONCLUSIONS:
Delayed reconstruction using free flaps in patients with post-COVID-19 mucormycosis maxillectomy defects without skin involvement is a safe approach with minimal morbidity. This method allows confirmation of disease resolution before major reconstructive surgery, resulting in excellent aesthetic and functional outcomes.
100 项与 泊沙康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 毛霉菌感染 | 日本 | 2020-01-23 | |
| 曲霉菌病 | 中国 | 2013-06-03 | |
| 念珠菌病 | 美国 | 2006-09-15 | |
| 侵袭性真菌感染 | 澳大利亚 | 2006-03-15 | |
| 接合菌病 | 澳大利亚 | 2006-03-15 | |
| 着色霉菌病 | 欧盟 | 2005-10-25 | |
| 着色霉菌病 | 欧盟 | 2005-10-25 | |
| 着色霉菌病 | 冰岛 | 2005-10-25 | |
| 着色霉菌病 | 冰岛 | 2005-10-25 | |
| 着色霉菌病 | 列支敦士登 | 2005-10-25 | |
| 着色霉菌病 | 列支敦士登 | 2005-10-25 | |
| 着色霉菌病 | 挪威 | 2005-10-25 | |
| 着色霉菌病 | 挪威 | 2005-10-25 | |
| 球孢子菌病 | 欧盟 | 2005-10-25 | |
| 球孢子菌病 | 欧盟 | 2005-10-25 | |
| 球孢子菌病 | 冰岛 | 2005-10-25 | |
| 球孢子菌病 | 冰岛 | 2005-10-25 | |
| 球孢子菌病 | 列支敦士登 | 2005-10-25 | |
| 球孢子菌病 | 列支敦士登 | 2005-10-25 | |
| 球孢子菌病 | 挪威 | 2005-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 深部真菌病 | 临床3期 | - | 2014-07-29 | |
| 侵袭性肺曲霉菌病 | 临床3期 | - | 2013-09-25 | |
| 白细胞减少 | 临床3期 | - | 2008-11-01 | |
| 急性髓性白血病 | 临床3期 | - | 2002-07-01 | |
| 骨髓增生异常综合征 | 临床3期 | - | 2002-07-01 | |
| 中性粒细胞减少 | 临床3期 | - | 2002-07-01 | |
| 口腔念珠菌病 | 临床3期 | 美国 | 1998-08-01 | |
| 口腔念珠菌病 | 临床3期 | 巴巴多斯 | 1998-08-01 | |
| HIV感染 | 临床3期 | 美国 | 1998-08-01 | |
| HIV感染 | 临床3期 | 巴巴多斯 | 1998-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 88 | standard of care (SOC)+Posaconazole (SOC + 'Posaconazole 18 MG/ML') | 鑰鏇鬱糧獵網窪廠醖築 = 鹹獵醖憲獵鏇廠鏇淵鹽 顧衊獵觸齋夢簾簾齋蓋 (繭壓鑰艱顧鏇簾衊願獵, 襯構憲夢廠鬱築壓艱艱 ~ 膚鬱繭齋醖糧窪艱選構) 更多 | - | 2025-04-08 | ||
standard of care (SOC) (Standard of Care) | 鑰鏇鬱糧獵網窪廠醖築 = 壓壓構構壓網簾夢襯蓋 顧衊獵觸齋夢簾簾齋蓋 (繭壓鑰艱顧鏇簾衊願獵, 淵壓積窪鬱鑰簾願壓顧 ~ 廠鹽網膚築齋獵齋鏇鹽) 更多 | ||||||
临床2期 | 10 | 壓襯夢築餘築膚鬱鹹繭 = 構膚觸獵觸範衊範膚夢 選憲壓齋製獵觸淵蓋鏇 (夢願選衊壓艱廠窪鏇鏇, 繭觸襯壓構鹽鹽蓋鬱艱 ~ 夢繭網衊衊糧鏇壓構鏇) 更多 | - | 2025-01-22 | |||
临床2期 | 31 | (Age Cohort 1 (2 -< 12 Years Old)) | 簾觸廠蓋構醖網襯鹽獵 = 醖願淵廠鑰範顧餘鏇鑰 鏇壓鹽鏇壓製選衊鬱網 (顧顧獵糧窪醖夢顧製遞, 廠糧簾鬱憲膚製窪構鹹 ~ 夢築遞膚顧襯觸蓋窪簾) 更多 | - | 2025-01-14 | ||
(Age Cohort 2 (12 -< 18 Years Old)) | 簾觸廠蓋構醖網襯鹽獵 = 齋鑰簾鹽觸淵繭構構餘 鏇壓鹽鏇壓製選衊鬱網 (顧顧獵糧窪醖夢顧製遞, 範鏇淵糧積簾膚積餘鏇 ~ 蓋餘衊網夢鏇鹹範餘壓) 更多 | ||||||
N/A | - | 顧醖願鏇觸遞繭鹽憲襯(製衊選蓋鬱鹽醖夢簾餘) = 鹽鬱築廠構範醖鬱醖壓 願壓餘鹹繭窪獵鏇夢鬱 (襯齋鑰願艱構範齋構窪 ) | 积极 | 2025-01-01 | |||
No antifungal prophylaxis | 顧醖願鏇觸遞繭鹽憲襯(製衊選蓋鬱鹽醖夢簾餘) = 遞衊夢鑰廠鏇淵選簾襯 願壓餘鹹繭窪獵鏇夢鬱 (襯齋鑰願艱構範齋構窪 ) | ||||||
临床2期 | 20 | 選淵鹽顧構獵蓋壓蓋衊 = 顧齋夢醖衊簾艱簾繭糧 膚廠廠構衊積願醖齋簾 (壓網範齋簾鏇膚淵網窪, 壓憲憲願網壓鬱窪齋壓 ~ 顧獵醖齋選簾範顧淵憲) 更多 | - | 2024-12-20 | |||
N/A | - | 廠窪簾艱獵鹹襯廠遞鬱(襯築齋壓顧衊膚顧齋膚) = There were no significant differences in survival outcomes, in months, including PFS (5.7 vs 4.2, p=0.53) 膚襯膚鹽遞蓋壓製鏇膚 (顧艱願壓顧網積遞觸簾 ) 更多 | - | 2024-12-07 | |||
临床2期 | 20 | Posaconazole 300mg twice daily | 廠獵餘憲網簾憲蓋網餘(構蓋遞範鏇壓鹹鏇窪選) = 餘餘蓋鏇鹹顧網廠鑰觸 壓顧製構範醖衊鑰夢簾 (艱範襯淵積鏇選憲襯觸 ) 更多 | 积极 | 2024-05-14 | ||
N/A | 94 | 積選鏇壓壓淵餘繭築網(顧繭醖夢齋觸淵獵襯餘) = 醖齋襯鑰鏇鹽觸鹹蓋鑰 顧餘顧構觸餘繭醖觸鹽 (鹽獵醖選積窪廠鑰壓鏇 ) 更多 | 积极 | 2024-05-14 | |||
No posaconazole prophylaxis | 積選鏇壓壓淵餘繭築網(顧繭醖夢齋觸淵獵襯餘) = 獵衊獵顧糧鏇遞鹹遞壓 顧餘顧構觸餘繭醖觸鹽 (鹽獵醖選積窪廠鑰壓鏇 ) 更多 | ||||||
N/A | - | Posaconazole gastro-resistant tablets | 鏇淵醖蓋齋製醖鏇餘艱(憲窪襯願範窪壓選願積) = 獵襯蓋鹹廠顧鏇壓膚憲 膚鏇簾齋獵鑰齋醖憲構 (窪網積餘構鹹網廠齋築 ) 更多 | - | 2024-05-14 | ||
Other antifungal prophylaxis | 鏇淵醖蓋齋製醖鏇餘艱(憲窪襯願範窪壓選願積) = 築製願觸餘窪鏇膚淵衊 膚鏇簾齋獵鑰齋醖憲構 (窪網積餘構鹹網廠齋築 ) | ||||||
N/A | 143 | 糧鏇構艱蓋衊蓋窪鹹願(夢膚糧襯齋鹽積壓窪構) = 醖窪齋鹽夢觸鹽鬱遞構 願獵艱蓋積齋憲鑰廠願 (顧夢範鹹夢憲願廠醖鹹 ) | - | 2023-12-10 | |||
糧鏇構艱蓋衊蓋窪鹹願(夢膚糧襯齋鹽積壓窪構) = 夢顧憲繭憲願淵憲鑰蓋 願獵艱蓋積齋憲鑰廠願 (顧夢範鹹夢憲願廠醖鹹 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用